The University of Southampton
University of Southampton Institutional Repository

Serum PRO-C3 is useful for risk prediction and fibrosis assessment in MAFLD with chronic kidney disease in an Asian cohort

Serum PRO-C3 is useful for risk prediction and fibrosis assessment in MAFLD with chronic kidney disease in an Asian cohort
Serum PRO-C3 is useful for risk prediction and fibrosis assessment in MAFLD with chronic kidney disease in an Asian cohort
Background: metabolic dysfunction-associated fatty liver disease (MAFLD) is an emerging risk factor for chronic kidney disease (CKD). N-terminal propeptide of collagen type 3 (PRO-C3) is a biomarker of advanced fibrosis in MAFLD and PRO-C3 may be involved in renal fibrosis. We aimed to use PRO-C3 measurements to generate a new algorithmic score to test the prediction of MAFLD with chronic kidney disease (MAFLD–CKD).

Methods: a derivation and independent validation cohort of 750 and 129 Asian patients with biopsy-confirmed MAFLD were included. Serum PRO-C3 concentration was measured and regression analyses were performed to examine associations with MAFLD–CKD. A derivative algorithm for MAFLD–CKD risk prediction was evaluated with receiver operator characteristic (ROC) curve analysis.

Results: the study included two Asian cohorts (n = 180 with MAFLD–CKD; mean-eGFR: 94.93 mL/min/1.73 m2; median-urinary albumin-to-creatinine ratio: 6.58 mg/mmol). PRO-C3 was associated with the severity of MAFLD-CKD and independently associated with MAFLD–CKD (adjusted odds ratio = 1.16, 95% confidence interval [CI]: 1.08–1.23, p < .001). A new non-invasive score (termed PERIOD) including PRO-C3 efficiently predicted MAFLD-CKD (AUROC = .842, 95% CI: .805–.875). Accuracy, specificity and negative predictive values were 80.2%, 85.1% and 88.4%, respectively. In the validation cohort, the PERIOD score had good diagnostic performance (AUROC = .807, 95% CI: .691–.893) with similar results in all patient subgroups. In the MAFLD–CKD subgroup, the accuracy for identifying advanced fibrosis was further improved by combining the PRO-C3-based ADAPT with the Agile 3+ scores (AUROC = .90, 95% CI: .836–.964).

Conclusions: the PERIOD score is helpful for accurately predicting the risk of MAFLD–CKD. PRO-C3 can also be used to assess liver fibrosis in people with MAFLD–CKD.
N-terminal propeptide of type 3 collagen, chronic kidney disease, liver fibrosis, metabolic dysfunction-associated fatty liver disease, metabolic dysfunction-associated steatotic liver disease, risk prediction
1478-3223
1129-1141
Tang, Liang-Jie
586390dd-64da-4988-86e0-c3ea141cffc3
Sun, Dan-Qin
56d2d368-71df-400a-8a1d-a62afdce5771
Song, Sherlot Juan
6567e42e-2057-444f-97ab-29597ff4d056
Byrne, Christopher D.
1370b997-cead-4229-83a7-53301ed2a43c
et al.
Tang, Liang-Jie
586390dd-64da-4988-86e0-c3ea141cffc3
Sun, Dan-Qin
56d2d368-71df-400a-8a1d-a62afdce5771
Song, Sherlot Juan
6567e42e-2057-444f-97ab-29597ff4d056
Byrne, Christopher D.
1370b997-cead-4229-83a7-53301ed2a43c

Tang, Liang-Jie, Sun, Dan-Qin and Song, Sherlot Juan , et al. (2024) Serum PRO-C3 is useful for risk prediction and fibrosis assessment in MAFLD with chronic kidney disease in an Asian cohort. Liver International, 44 (5), 1129-1141. (doi:10.1111/liv.15878).

Record type: Article

Abstract

Background: metabolic dysfunction-associated fatty liver disease (MAFLD) is an emerging risk factor for chronic kidney disease (CKD). N-terminal propeptide of collagen type 3 (PRO-C3) is a biomarker of advanced fibrosis in MAFLD and PRO-C3 may be involved in renal fibrosis. We aimed to use PRO-C3 measurements to generate a new algorithmic score to test the prediction of MAFLD with chronic kidney disease (MAFLD–CKD).

Methods: a derivation and independent validation cohort of 750 and 129 Asian patients with biopsy-confirmed MAFLD were included. Serum PRO-C3 concentration was measured and regression analyses were performed to examine associations with MAFLD–CKD. A derivative algorithm for MAFLD–CKD risk prediction was evaluated with receiver operator characteristic (ROC) curve analysis.

Results: the study included two Asian cohorts (n = 180 with MAFLD–CKD; mean-eGFR: 94.93 mL/min/1.73 m2; median-urinary albumin-to-creatinine ratio: 6.58 mg/mmol). PRO-C3 was associated with the severity of MAFLD-CKD and independently associated with MAFLD–CKD (adjusted odds ratio = 1.16, 95% confidence interval [CI]: 1.08–1.23, p < .001). A new non-invasive score (termed PERIOD) including PRO-C3 efficiently predicted MAFLD-CKD (AUROC = .842, 95% CI: .805–.875). Accuracy, specificity and negative predictive values were 80.2%, 85.1% and 88.4%, respectively. In the validation cohort, the PERIOD score had good diagnostic performance (AUROC = .807, 95% CI: .691–.893) with similar results in all patient subgroups. In the MAFLD–CKD subgroup, the accuracy for identifying advanced fibrosis was further improved by combining the PRO-C3-based ADAPT with the Agile 3+ scores (AUROC = .90, 95% CI: .836–.964).

Conclusions: the PERIOD score is helpful for accurately predicting the risk of MAFLD–CKD. PRO-C3 can also be used to assess liver fibrosis in people with MAFLD–CKD.

Text
Manuscript_R1 - Accepted Manuscript
Restricted to Repository staff only until 9 February 2025.
Request a copy
Text
Supplementary Table 1_R1 - Accepted Manuscript
Restricted to Repository staff only until 9 February 2025.
Request a copy
Text
Supplementary Table 2_R1 - Accepted Manuscript
Restricted to Repository staff only until 9 February 2025.
Request a copy
Text
Supplementary Table 3_R1 - Accepted Manuscript
Restricted to Repository staff only until 9 February 2025.
Request a copy
Text
Supplementary Table 4_R1 - Accepted Manuscript
Restricted to Repository staff only until 9 February 2025.
Request a copy
Text
Supplementary Table 5_R1 - Accepted Manuscript
Restricted to Repository staff only until 9 February 2025.
Request a copy
Text
Supplementary Table 6_R1 - Accepted Manuscript
Restricted to Repository staff only until 9 February 2025.
Request a copy
Text
Table 1_R1 - Accepted Manuscript
Restricted to Repository staff only until 9 February 2025.
Request a copy
Text
Table 2_R1 - Accepted Manuscript
Restricted to Repository staff only until 9 February 2025.
Request a copy
Image
Figure 1_R1 - Accepted Manuscript
Restricted to Repository staff only until 9 February 2025.
Request a copy
Image
Figure 2_R1 - Accepted Manuscript
Restricted to Repository staff only until 9 February 2025.
Request a copy
Image
Figure 3_R1 - Accepted Manuscript
Restricted to Repository staff only until 9 February 2025.
Request a copy
Image
Figure 4_R1 - Accepted Manuscript
Restricted to Repository staff only until 9 February 2025.
Request a copy
Image
Graphic abstract_R1 - Accepted Manuscript
Restricted to Repository staff only until 9 February 2025.
Request a copy
Image
Supplementary Figure 1 - Accepted Manuscript
Restricted to Repository staff only until 9 February 2025.
Request a copy
Image
Supplementary Figure 2 - Accepted Manuscript
Restricted to Repository staff only until 9 February 2025.
Request a copy

Show all 16 downloads.

More information

Accepted/In Press date: 9 February 2024
Published date: May 2024
Keywords: N-terminal propeptide of type 3 collagen, chronic kidney disease, liver fibrosis, metabolic dysfunction-associated fatty liver disease, metabolic dysfunction-associated steatotic liver disease, risk prediction

Identifiers

Local EPrints ID: 487138
URI: http://eprints.soton.ac.uk/id/eprint/487138
ISSN: 1478-3223
PURE UUID: f7449166-91dc-47a9-bf77-dc9028a927f5
ORCID for Christopher D. Byrne: ORCID iD orcid.org/0000-0001-6322-7753

Catalogue record

Date deposited: 14 Feb 2024 17:38
Last modified: 22 May 2024 01:36

Export record

Altmetrics

Contributors

Author: Liang-Jie Tang
Author: Dan-Qin Sun
Author: Sherlot Juan Song
Corporate Author: et al.

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×